(June 11, 2024)- “We are encouraged by the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee’s unanimous approval of donanemab and are optimistic that, if fully approved by the FDA, it will make a positive difference in the lives of individuals living with Alzheimer’s disease and their family caregivers. The FDA should keep the review process moving forward and set a date for final determination.
“This is a positive sign of continuing progress, but we must keep moving forward toward the finish line, which is a cure for Alzheimer’s disease. Federal policymakers must continue increasing investments in Alzheimer’s disease research and support services for caregivers.”